Who is sponsoring NCT05315856?

NCT05315856 is sponsored by Korea University Guro Hospital.

What drugs are being tested in NCT05315856?

Interventions in NCT05315856: either BNT162b2 or ChAdOx1 vaccine.

What condition does NCT05315856 study?

NCT05315856 studies COVID-19 Vaccination, Inflammation, Vaccine Immune Response, Vaccine Adverse Reaction.

Is NCT05315856 still recruiting?

NCT05315856 is currently status unknown. Last updated 7 April 2022.

Last reviewed 2022-04-07 · How we verify

NCT05315856

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reactogenicity, Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms

Status unknown Last updated 7 April 2022

What this trial tests

trial testing either BNT162b2 or ChAdOx1 vaccine in COVID-19 Vaccination in 120 participants. Status unknown.

Timeline

1 March 2021

Primary endpoint
31 May 2022

31 December 2022

Quick facts

Lead sponsor	Korea University Guro Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	120
Start date	1 March 2021
Primary completion	31 May 2022
Estimated completion	31 December 2022
Sites	3 locations across South Korea

Drugs / interventions tested

either BNT162b2 or ChAdOx1 vaccine — full drug profile →

Conditions studied

COVID-19 Vaccination — all drugs for COVID-19 Vaccination →
Inflammation — all drugs for Inflammation →
Vaccine Immune Response — all drugs for Vaccine Immune Response →
Vaccine Adverse Reaction — all drugs for Vaccine Adverse Reaction →

Sponsor

Korea University Guro Hospital

Who can join

Adults 19 to 59, any sex, with COVID-19 Vaccination or Inflammation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Analysis of humoral antibody and cytokine kinetics after vaccination with either BNT162b2 or ChAdOx1 nCoV-19 vaccine and factors influencing the vaccine immunogenicity

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Evolving Horizons: Adenovirus Vectors' Timeless Influence on Cancer, Gene Therapy and Vaccines.
Trivedi PD, Byrne BJ, Corti M. · · 2023 · cited 22× · PMID 38140619 · DOI 10.3390/v15122378
COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19.
Heo JY, Seo YB, Kim EJ, Lee J, et al · · 2022 · cited 16× · PMID 36119092 · DOI 10.3389/fimmu.2022.975363

Verify or expand the search:

Other recruiting trials for COVID-19 Vaccination

Currently open trials in the same condition.

NCT06923137 — A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much · active not recruiting
NCT06613984 — Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran) · active not recruiting
NCT06156254 — Community Care Intervention to Decrease COVID-19 Vaccination Inequities · NA · recruiting
NCT04967807 — Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study) · NA · active not recruiting
NCT04980560 — Gut Microbiota Profile and Its Impact on Immunity Status in COVID-19 Vaccinated Cohorts · active not recruiting

Other Korea University Guro Hospital trials

Trials by the same sponsor.

NCT07009769 — AI-Driven Precision Diagnostic System for Lung Cancer Based on Liquid Biopsy · completed
NCT06752733 — Cardiac Stunning After Electrical Cardioversion · active not recruiting
NCT06202690 — SP Robotic Versus VATS Anatomical Pulmonary Resection for Patients With NSCLC · NA · not yet recruiting
NCT06889259 — Efficacy and Safety of CBT on Tinnitus · NA · completed
NCT05704621 — Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Mai · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05315856 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Korea University Guro Hospital
Last refreshed: 7 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05315856.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing